Orexigen Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, announced they ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Hot Corp. News Management Comments

RBC Capital Sees Tough Road Ahead Following Orexigen Therapeutics' (OREX) Takeda Partnership Termination; Cuts PT to $0.60 March 16, 2016 9:46 AM Leerink Lowers Leerink (OREX) PT to $1 on Move to Acquire Contrave Rights from TakedaMarch 16, 2016 7:56 AM Piper Jaffray Downgrades Orexigen Therapeutics (OREX) to NeutralMarch 16, 2016 6:35 AM JMP Securities Downgrades Orexigen Therapeutics (OREX) to Market PerformMarch 16, 2016 6:34 AM Orexigen Therapeutics to Host Conference Call at 8:30 a.m. Eastern Time Today to Discuss Acquisition of U.S. Rights to Contrave® (naltrexone HCl / bupropion HCl extended release) and Central and EastMarch 15, 2016 7:05 AM Orexigen Therapeutics (OREX) Enters Mysimba Commercialization Agreement with Valeant (VRX)March 15, 2016 7:03 AM Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Pharmaceuticals for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) for 18 Central and EasternMarch 15, 2016 7:00 AM Orexigen announces strategic acquisition of all U.S. rights to Contrave®, the market leading branded anti-obesity prescription medicineMarch 15, 2016 7:00 AM Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE® in the United StatesMarch 15, 2016 7:00 AM